Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Nu.Q® H3.1 Immunoassay for NETs Quantification

Monday, July 7, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Nu.Q® H3.1 is a novel chemiluminescent immunoassay designed for the precise quantification of neutrophil extracellular traps (NETs) in plasma. This assay demonstrates high specificity and reproducibility, making it particularly useful for research into NET-related conditions such as sepsis, COVID-19, and autoimmune diseases. Additional resources are available for further exploration of its applications.
Price reaction · baseline $14.8 (2025-07-03 close) · hit pre-market · 1 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-9%
day 1
-4.6%
day 3
-8.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Nu.Q® H3.1 offers high specificity and reproducibility.
  • It is suitable for studying various NET-related pathologies.
  • The assay is engineered for accurate quantification.

Full Press Release Details

Nu.Q® H3.1 is an advanced chemiluminescent immunoassay engineered for accurate and standardized quantification of neutrophil extracellular traps (NETs) via H3.1-nucleosomes in plasma. Nu.Q® H3.1 delivers high specificity and reproducibility, making it ideal for studying NET-related pathologies such as sepsis, COVID-19, and autoimmune diseases.
Learn more about Nu.Q® Discover
Download our application notes to find out more about this assay.

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is Nu.Q® H3.1?

Nu.Q® H3.1 is a chemiluminescent immunoassay for quantifying neutrophil extracellular traps.

What conditions can Nu.Q® H3.1 help study?

It is useful for studying sepsis, COVID-19, and autoimmune diseases.

What are the benefits of Nu.Q® H3.1?

It offers high specificity and reproducibility for accurate NETs quantification.

Where can I find more information about Nu.Q® H3.1?

Additional details and application notes are available for download.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Nu.Q® H3.1 neutrophil extracellular traps NETs quantification sepsis COVID-19
Last updated: Jul 7, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk